Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response

The post Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints appeared first on Pharmaceutical Business review.

Aytu BioScience to acquire Innovus Pharmaceuticals

This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone

The post Aytu BioScience to acquire Innovus Pharmaceuticals appeared first on Pharmaceutical Business review.

FDA approves GSK’s Nucala for young children with severe eosinophilic asthma

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval

The post FDA approves GSK’s Nucala for young children with severe eosinophilic asthma appeared first on Pharmaceutical Business review.

VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent

The post VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma appeared first on Pharmaceutical Business review.

Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas

Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success

The post Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas appeared first on Pharmaceutical Business review.

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung

The post Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study appeared first on Pharmaceutical Business review.

FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia

GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be

The post FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia appeared first on Pharmaceutical Business review.

Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid cells in

The post Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis appeared first on Pharmaceutical Business review.

Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK

Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI

The post Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK appeared first on Pharmaceutical Business review.

Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal

The post Esketamine nasal spray reduces depressive symptoms in two phase 3 studies appeared first on Pharmaceutical Business review.